Brought to you by 
GenVec sells off its myoblast cell therapy program for CHF
06 Dec 2022
Executive Summary
GenVec (developing cancer, cardiovascular, and ophthalmic drug candidates) has signed a letter of intent to sell its myoblast cell therapy program for congestive heart failure to a newly formed, undisclosed company.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GenVec sells off its myoblast cell therapy program for CHF
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice